title: Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients.
abstract: OBJECTIVE
  Our purpose was to determine whether urinary interleukin-8 (IL-8) levels could be used to predict a tumor-free response to intravesical bacillus Calmette-Guerin (BCG) therapy in bladder cancer patients.
  
  
  METHODS
  A total of 46 patients with superficial bladder cancer underwent an initial 6-week course of intravesical BCG therapy after transurethral resection. Voided urine samples were collected immediately before BCG instillations 1 and 6. Urine samples were centrifuged at 1,500 rpm for 8 minutes, and the supernatant was stored at -20 C. An enzyme-linked immunosorbent assay technique was used to measure urinary IL-8 levels. The Jaffé method was used to measure urinary creatinine. Results were expressed as the IL-8/creatinine ratio. Patients were followed with cystoscopy and urinary cytology every 3 months to detect bladder tumor recurrence.
  
  
  RESULTS
  IL-8/creatinine ratios were measured in 31 patients before BCG therapy and were undetectable in 15. After 5 weeks of intravesical BCG therapy, IL-8/creatinine ratios fell in 27 patients (59%), were unchanged in 10 (22%) and rose in 9 (19%). Mean followup was 20.9 months (range 3 to 48). There was no association between the direction of change in IL-8/creatinine ratio and response to intravesical BCG therapy (p = 0.5).
  
  
  CONCLUSIONS
  Urinary IL-8 levels obtained before intravesical BCG therapy and after instillation 5 of BCG were not helpful in predicting tumor recurrences in bladder cancer patients.
authors.affiliation: Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
authors.forename: R
authors.initials: R
authors.lastname: Rabinowitz
authors.forename: D S
authors.initials: DS
authors.lastname: Smith
authors.forename: D D
authors.initials: DD
authors.lastname: Tiemann
authors.forename: M A
authors.initials: MA
authors.lastname: Hudson
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000652:urine*; D003404:Creatinine / Q000652:urine*; D006801:Humans; D016209:Interleukin-8 / Q000652:urine*; D011237:Predictive Value of Tests; D001749:Urinary Bladder Neoplasms / Q000628:therapy* / Q000652:urine*
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D016209:Interleukin-8; D003404:Creatinine